argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 10/22/20
argenx Reports Third Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 10/22/20
argenx to Report Third Quarter 2020 Financial Results and Business Update on October 22, 2020GlobeNewsWire • 10/15/20
argenx Expands Capabilities In Antibody Engineering Through Key Technology PartnershipsGlobeNewsWire • 10/06/20
argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific SessionGlobeNewsWire • 10/05/20
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/02/20
argenx reports half year 2020 financial results and provides second quarter business updateGlobeNewsWire • 07/30/20
argenx (ARGX): Strong Industry, Solid Earnings Estimate RevisionsZacks Investment Research • 07/01/20
argenx announces full exercise of underwriters’ option to purchase additional ADSsGlobeNewsWire • 05/29/20
argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia GravisGlobeNewsWire • 05/26/20
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/15/20
argenx reports first quarter 2020 financial results and provides business updateGlobeNewsWire • 05/14/20
Market Fairly Evaluates Argenx's Efgartigimod (ARGX-113) In Myasthenia GravisSeeking Alpha • 04/06/20
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/28/20